Facebook
Twitter
LinkedIn
ForwardAnticoagulation for VTE & Management of VTE Part I
Expert Panelist Lead: Ian Jenkins MD and Scott Kaatz DO, MSC, FACP, FHM
Accreditation and Designation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Blackwell Futura Media Services and the Society of Hospital Medicine Blackwell Futura Media Services is accredited by the ACCME to provide continuing medical education for physicians.”
Blackwell Futura Media Services designates this enduring material for a maximum of (1 CREDIT) AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Educational Objectives
Upon completion of this educational activity, participants will be better able to:
The need for this educational activity is to inform hospitalists and pharmacists on ways to improve inpatient anticoagulation management with a focus on best practices and methods to ‘hard wire’ these outline processes so they have a large positive impact on the quality and safety of patient care.
Series List
Activity 1 – Management of Target Specific Oral Anticoagulants (TSOACs) in the Inpatient and Perioperative Setting
Activity 2 – The Inpatient Management of Anticoagulation for Patients with Atrial Fibrillation
Activity 3 – Anticoagulation for VTE & Management of VTE Part I
Activity 4 – Anticoagulation for VTE & Management of VTE Part II
Activity 5 – Reversal of New Oral Anticoagulants
Activity 6 – Establishing Inpatient Programs to Improve Anticoagulation Management
Activity 7 – Periprocedural Management of Anticoagulants
This activity is supported by an educational grant from Daichii Sankyo, Inc.
Expert Panelist Lead: Ian Jenkins MD- University of California, San Diego, CA has no conflicts of interest to disclose
Expert Panelist: Allison Burnett PharmD, PhC, CACP- University of New Mexico, Albuquerque, NM has no conflicts of interest to disclose
Expert Panelist: Margaret Fang MD- University of California, San Fransico, CA has no conflicts of interest to disclose
Expert Panelist Lead: Scott Kaatz DO, MSC, FACP, FHM- Hurley Medical Center, Flint, MI)
• Grant support (to institution)
– Boehringer Ingelheim
– Bristol-Myers Squibb
– Janssen
– Eisai
– Iverson Genetic Diagnostics/Medicare
– National Institutes of Health
– Canadian Institutes of Health Research
– Blue Cross/Blue Shield of Michigan
• Speaker honorarium
– Janssen
– Boehringer Ingelheim
– Bristol-Myers Squibb/Pfizer
– CSL Behring
• Consultant
– Boehringer Ingelheim
– Bristol-Myers Squibb/Pfizer
– Janssen
– Daiichi Sankyo
• Board membership (non-profit)
– Anticoagulation Forum
– Thrombosis and Hemostasis Societies of North America
– National Certification Board for Anticoagulation Providers
– National Blood Clot Alliance Medical Scientific Advisory Board
SHM CONFLICT OF INTEREST DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, SHM requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. SHM resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. All relevant financial relationships shall be disclosed to participants prior to the start of the activity.
Furthermore, SHM seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SHM is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.
Available Credit
- 0.75 AMA PRA Category 1 Credit™
- 0.75 Non-physician